CTXR
Citius Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.60
+2.06%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.59
From 52W high−67.03%
Volume279877.00
Market cap$16.47M
P/E (TTM)—
P/S (TTM)2.3x
Div yield—
Key dataSep 18, 2026
Open
$0.59
From 52W high
−67.03%
Volume
279877.00
Market cap
$16.47M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
49.5
MomentumView details →
1D Return
+2.06%
YTD Return
−24.04%
SummaryUpdated Jun 1, 2026
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company founded in 2007 and headquartered in Cranford, New Jersey. The company went public in October 2014 and focuses on developing critical care products, particularly anti-infective treatments for cancer care, prescription therapeutics, and advanced stem cell therapies. As a clinical-stage biotechnology company, Citius has built a pipeline of five proprietary products targeting various medical conditions, from catheter-related infections to cancer treatments, though it has yet to generate substantial commercial revenues from these developments.
Similar companies
Latest newsMore news →
Citius Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2026, with $7.1 million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR and $17 million in cash and cash equivalents as of June 30, 2026.37d agoCitius Oncology appointed Jonathan Peri as an independent director to its board.39d ago